Phone
EmailPhoneEmail
Mundipharma International
Manufacturing · United Kingdom · 2,877 Employees
View Company Info for Free
About
Headquarters
Cambridge Science Park Milton Rd, Cambridge, Ca...Phone Number
+44 1223424211Website
www.mundipharma.comRevenue
$1.9 BillionIndustry
Who is Mundipharma International
Mundipharma International is a pharmaceutical company that develops partnerships with a wide range of pharmaceutical and biotech companies around Europe and the rest of the world. Mundipharma engages in the research and development of pain, oncology, inflammatory, and respiratory disease treatments for patients. Mundipharma International is based in the United Kingdom.Read more
Popular SearchesMundipharma InternationalMundipharmaMundipharma Pty LtdMundipharma International LtdMundipharma Pharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Show moreMundipharma International Org Chart
PhoneEmailPhoneEmail
Mundipharma International Company Metrics
Acquisitions & Subsidiaries
Jul 18, 2022
Mundipharma
Jul 18, 2022
Mundipharma
Jul 18, 2022
Mundipharma Pharmaceuticals Sdn Bhd
Jul 18, 2022
Taiwan Mundipharma Pharmaceuticals
Jul 18, 2022
Mundipharma Biologics
Jul 18, 2022
Mundipharma Oy
See More Acquisitions & Subsidiaries
Mundipharma International Tech Stack
A closer look at the technologies used by Mundipharma International
Top Companies in United Kingdom
Top 10 companies in United Kingdom by revenue
Top 10 companies in United Kingdom by number of employees
Top 10 companies in United Kingdom by total funding amount
Mundipharma International News & Media
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area
CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3Apr 24, 2024Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint
CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of aApr 16, 2024Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults
CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and is based on results from the pivotal ReSTORE Phase III clinical trial, which demonstrated statistical non-inferiority* for rezafungin, dosed once weekly, when comparDec 22, 2023Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1
CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1 The CHMP based its positive opinion on results from the pivotal ReSTORE Phase III clinical trial, which demonstrated statistical non-inferiority* for rezafungin, dosOct 13, 2023Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
BEIJING, Aug. 1, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an Assignment Agreement (the "Agreement") with...Aug 1, 2023
Read more news
Frequently Asked Questions regarding Mundipharma International
Mundipharma International is a pharmaceutical company that develops partnerships with a wide range of pharmaceutical and biotech companies around Europe and the rest of the world. Mundipharma engages in the research and development of pain, oncology, inflammatory, and respiratory disease treatments for patients. Mundipharma International is based i... Read More
